Home

Loading...

Table of contents

Malignant central airway obstruction

What's new

Added 2024 WABIP and 2023 ESMO guidelines for the management of malignant central airway obstruction.

Background

Overview

Definition
MCAO is the narrowing or complete blockage of the trachea, mainstem bronchi, or bronchus intermedius due to malignant tumors.
1
Pathophysiology
The pathophysiology of MCAO involves the growth of a malignant tumor within the central airways, leading to impaired airflow. This obstruction can cause a ventilation-perfusion mismatch, leading to hypoxemia. In severe cases, complete obstruction can lead to atelectasis of the affected lung segment or lobe, post-obstructive pneumonia, and respiratory failure.
2
Epidemiology
It is estimated that 20-30% of patients with lung cancer will experience airway obstruction-associated complications, including dyspnea, atelectasis, and pneumonia.
3
Disease course
The clinical course of MCAO typically involves symptoms such as dyspnea, stridor, wheezing, cough, and hemoptysis. Symptoms can be exertional in the mild or early stages and become severe and present at rest over time.
2

Guidelines

Key sources

The following summarized guidelines for the management of malignant central airway obstruction are prepared by our editorial team based on guidelines from the World Association for Bronchology and Interventional Pulmonology (WABIP 2024), the European Society of Medical Oncology (ESMO 2023), and the American College of Chest Physicians (ACCP 2013). ...
Show more

Therapeutic procedures

Therapeutic bronchoscopy: as per ESMO 2023 guidelines, consider performing endoscopic debulking by laser, cryotherapy, or airway stenting in patients with lung cancer and symptomatic major airway obstruction or post-obstructive infection.
C
Create free account

More topics in this section

  • Airway stenting

  • EBRT